For the BRAF-mut CRC members of this site, I wanted to draw your attention to a recent pilot clinical trial publication (Sloan-Kettering) which showed clinical activity in 10 out of 12 patients by co-dosing the BRAF inhibitor vemurafenib & the anti-EGFR antibody panitumumab. It is a very new publication, so your Onc might not be aware of it yet - I suggest bringing it to his/her attention for discussion.
Citation: Rona Yaeger et al. "Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients" Clinical Cancer Research (2015)
Hyperlink: http://clincancerres.aacrjournals.org/c ... l.pdf+html
Unlike in BRAF-mut melanoma, single agent BRAF inhibitors have not demonstrated much single agent activity in BRAF-mut CRC. The multiple parallel clinical trial drug combination studies are starting to show progress.